Anti-nerve growth factor in pain management: current evidence
Open Access
- 1 June 2016
- journal article
- review article
- Published by Informa UK Limited in Journal of Pain Research
- Vol. 9, 373-383
- https://doi.org/10.2147/jpr.s89061
Abstract
Anti-nerve growth factor in pain management: current evidence David S Chang,1 Eugene Hsu,2 Daniel G Hottinger,1 Steven P Cohen1,3–5 1Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, 2Clinical Excellence Research Center, Stanford University School of Medicine, Stanford, CA, 3Department of Anesthesiology, 4Department of Physical Medicine and Rehabilitation, Uniformed Services University of the Health Sciences, Bethesda 5Department of Physical Medicine and Rehabilitation, Johns Hopkins University School of Medicine, Baltimore, MD, USA There continues to be an unmet need for safe and effective pain medications. Opioids and nonsteroidal anti-inflammatory drugs (NSAIDs) dominate the clinical landscape despite limited effectiveness and considerable side-effect profiles. Although significant advancements have identified myriad potential pain targets over the past several decades, the majority of new pain pharmacotherapies have failed to come to market. The discovery of nerve growth factor (NGF) and its interaction with tropomyosin receptor kinase A (trkA) have been well characterized as important mediators of pain initiation and maintenance, and pharmacotherapies targeting this pathway have the potential to be considered promising methods in the treatment of a variety of nociceptive and neuropathic pain conditions. Several methodologic approaches, including sequestration of free NGF, prevention of NGF binding and trkA activation, and inhibition of trkA function, have been investigated in the development of new pharmacotherapies. Among these, NGF-sequestering antibodies have exhibited the most promise in clinical trials. However, in 2010, reports of rapid joint destruction leading to joint replacement prompted the Food and Drug Administration (FDA) to place a hold on all clinical trials involving anti-NGF antibodies. Although the FDA has since lifted this hold and a number of new trials are under way, the long-term efficacy and safety profile of anti-NGF antibodies are yet to be established. Keywords: nociceptive pain, neuropathic pain, drug discovery, tanezumab, fulranumab, fasinumabKeywords
This publication has 66 references indexed in Scilit:
- Scientometrics of drug discovery efforts: pain-related molecular targetsDrug Design, Development and Therapy, 2015
- Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodiesOsteoarthritis and Cartilage, 2015
- A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or kneeOsteoarthritis and Cartilage, 2015
- Nerve growth factor‐mediated regulation of pain signalling and proposed new intervention strategies in clinical pain managementJournal of Neurochemistry, 2013
- Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebo-controlled studyOsteoarthritis and Cartilage, 2011
- The effect of a monoclonal antibody to calcitonin-gene related peptide (CGRP) on injury-induced ectopic discharge following lingual nerve injuryNeuroscience Letters, 2011
- Antagonism of Nerve Growth Factor-TrkA Signaling and the Relief of PainAnesthesiology, 2011
- Phosphoinositide 3-Kinase Binds to TRPV1 and Mediates NGF-stimulated TRPV1 Trafficking to the Plasma MembraneThe Journal of general physiology, 2006
- Nerve growth factor mediates hyperalgesia and cachexia in auto-immune arthritisPain, 2005
- Nerve growth factor and gastric hyperalgesia in the ratNeurogastroenterology & Motility, 2003